Emerging biologics—checkpoint inhibitors, monoclonal antibodies, CAR T‑cells, bispecific antibodies, and oncolytic viruses—are transforming metastatic cancer care.
They target cancer cells with precision, boost immune response, and improve survival in melanoma, lung cancer, breast cancer, ovarian cancer, and blood cancers.
CAR T‑cell therapy achieves remission rates up to 90% in leukemia.
Visit Banish Cancer Blog for more.
#CancerInnovation #Immunotherapy #HealthEquity #BanishCancer
Shifting Paradigms: The Boundary of Immunotherapy
Medical research explores using immunotherapy, known for cancer treatment, to help depression patients by reducing inflammation. Learn about the new approach.
#Immunotherapy, #DepressionTreatment, #MedicalResearch, #MentalHealth, #Inflammation
https://newsletter.tf/immunotherapy-for-depression-new-hope-2026/
Doctors are now testing cancer treatments like immunotherapy for depression. This is a big change from just using it for cancer.
#Immunotherapy, #DepressionTreatment, #MedicalResearch, #MentalHealth, #Inflammation
https://newsletter.tf/immunotherapy-for-depression-new-hope-2026/
CAR-T Cell Therapy Shows Early Promise in Long-Term HIV Control
📰 Original title: Supercharging Immune Cells May Help Control HIV Long-Term
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅
View full AI summary: https://en.killbait.com/car-t-cell-therapy-shows-early-promise-in-long-term-hiv-control.html?utm_source=mastodon_world&utm_medium=social&utm_campaign=killbait.mastodon_world
A small clinical trial has demonstrated that CAR-T cell therapy, a treatment previously used for certain cancers, could help control HIV long-term. In the study, researchers reprogrammed participants' immune cells to specifically target HIV. Two participants achieved undetectable levels of the virus, maintaining viral suppression for nearly two years and almost a year, respectively, without the need for ongoing antiretroviral therapy. The trial involved nine participants, some of whom did not respond as well, highlighting the importance of early treatment and proper conditioning for the CAR-T cells. This approach aims to create 'sentinel' immune cells that remain active in the body to prevent HIV replication. Unlike prior HIV functional cures, which relied on stem cell transplants from rare donors and were complex and risky, CAR-T therapy could eventually provide a safer and more scalable alternative. Challenges remain, including the high cost and labor-intensive preparation of CAR-T cells, but researchers are exploring in-body production methods to simplify treatment. While the findings are preliminary, they provide a significant proof-of-concept that teaching the immune system to control HIV without continuous medication is possible, offering hope for a functional cure in the future.
CAR-T Cell Therapy Shows Early Promise in Long-Term HIV Control
📰 Original title: Supercharging Immune Cells May Help Control HIV Long-Term
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅
View full AI summary: https://en.killbait.com/car-t-cell-therapy-shows-early-promise-in-long-term-hiv-control.html?utm_source=mastodon_social&utm_medium=social&utm_campaign=killbait.mastodon_social
A small clinical trial has demonstrated that CAR-T cell therapy, a treatment previously used for certain cancers, could help control HIV long-term. In the study, researchers reprogrammed participants' immune cells to specifically target HIV. Two participants achieved undetectable levels of the virus, maintaining viral suppression for nearly two years and almost a year, respectively, without the need for ongoing antiretroviral therapy. The trial involved nine participants, some of whom did not respond as well, highlighting the importance of early treatment and proper conditioning for the CAR-T cells. This approach aims to create 'sentinel' immune cells that remain active in the body to prevent HIV replication. Unlike prior HIV functional cures, which relied on stem cell transplants from rare donors and were complex and risky, CAR-T therapy could eventually provide a safer and more scalable alternative. Challenges remain, including the high cost and labor-intensive preparation of CAR-T cells, but researchers are exploring in-body production methods to simplify treatment. While the findings are preliminary, they provide a significant proof-of-concept that teaching the immune system to control HIV without continuous medication is possible, offering hope for a functional cure in the future.
A Single Infusion Could Suppress H.I.V. for Years, Study Suggests
https://fed.brid.gy/r/https://www.nytimes.com/2026/05/11/health/hiv-infusion-immunotherapy.html
MANGANESE NANOPARTICLES SPARK IMMUNE FIRE, TARGETING CANCER
New manganese nanoparticles activate the body's defenses to fight cancer, showing fewer side effects than other treatments. Learn about this new therapy.
#CancerTreatment, #Immunotherapy, #Nanoparticles, #MedicalResearch, #HealthNews
https://newsletter.tf/manganese-nanoparticles-boost-immune-system-cancer/
Banish Cancer
NewsletterTF
The-14
KillBait News
KillBait
The New York Times - Breaking News, US News, World News and Videos [Unofficial]
All Scientifical
CBC Nova Scotia